ES2880795T3 - Péptidos aislados y fragmentos de los mismos a partir de fibrinógeno para la utilización como fármacos, particularmente en enfermedades inflamatorias de la piel - Google Patents

Péptidos aislados y fragmentos de los mismos a partir de fibrinógeno para la utilización como fármacos, particularmente en enfermedades inflamatorias de la piel Download PDF

Info

Publication number
ES2880795T3
ES2880795T3 ES16713796T ES16713796T ES2880795T3 ES 2880795 T3 ES2880795 T3 ES 2880795T3 ES 16713796 T ES16713796 T ES 16713796T ES 16713796 T ES16713796 T ES 16713796T ES 2880795 T3 ES2880795 T3 ES 2880795T3
Authority
ES
Spain
Prior art keywords
pos
acnes
fibrinogen
seq
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16713796T
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Dupin
Philippe Grange
Vincent Calvez
Joël Raingeaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Université Paris Cité
Université Paris-Saclay
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Universite de Paris
Université Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Universite de Paris, Université Paris-Saclay filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES2880795T3 publication Critical patent/ES2880795T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES16713796T 2015-03-20 2016-03-21 Péptidos aislados y fragmentos de los mismos a partir de fibrinógeno para la utilización como fármacos, particularmente en enfermedades inflamatorias de la piel Active ES2880795T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305414 2015-03-20
PCT/EP2016/056179 WO2016150926A1 (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Publications (1)

Publication Number Publication Date
ES2880795T3 true ES2880795T3 (es) 2021-11-25

Family

ID=52807757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16713796T Active ES2880795T3 (es) 2015-03-20 2016-03-21 Péptidos aislados y fragmentos de los mismos a partir de fibrinógeno para la utilización como fármacos, particularmente en enfermedades inflamatorias de la piel

Country Status (10)

Country Link
US (1) US10323078B2 (enExample)
EP (1) EP3270950B1 (enExample)
JP (1) JP6840086B2 (enExample)
CN (1) CN107636011B (enExample)
AU (1) AU2016236297B2 (enExample)
BR (1) BR112017020008A8 (enExample)
CA (1) CA2979812C (enExample)
DK (1) DK3270950T3 (enExample)
ES (1) ES2880795T3 (enExample)
WO (1) WO2016150926A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012866A1 (en) * 1989-04-10 1990-11-01 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
US5639940A (en) * 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1192183A2 (en) * 1999-06-30 2002-04-03 The Regents of the University of California Diagnostic test for thrombotic or thromboembolic disease
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi THE BLOOD GENERATING PEPTIDES AND THEIR USES
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2007535654A (ja) * 2003-04-23 2007-12-06 ハンサ メディカル アクチボラゲット 抗連鎖球菌物質の確認方法、及び連鎖球菌感染症治療のためのその使用
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
US20130280820A1 (en) * 2005-12-16 2013-10-24 Schering Corporation Biomarkers for psoriasis
US8445009B2 (en) * 2006-08-04 2013-05-21 Stb, Ltd Processes for the production of solid dressings for treating wounded tissue
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CN101618211A (zh) * 2008-07-03 2010-01-06 珠海联邦制药股份有限公司 一种乙肝多肽疫苗及其应用
AU2009268052B2 (en) * 2008-07-09 2015-05-28 Mallinckrodt Pharma Ip Trading D.A.C. Recombinant fibrinogen
WO2010054195A2 (en) 2008-11-07 2010-05-14 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
ES2929723T3 (es) * 2011-02-02 2022-12-01 Academisch Ziekenhuis Leiden Anticuerpos antiproteína carbamilada y el riesgo de padecer artritis

Also Published As

Publication number Publication date
US10323078B2 (en) 2019-06-18
JP6840086B2 (ja) 2021-03-10
CA2979812A1 (en) 2016-09-29
AU2016236297A1 (en) 2017-09-28
EP3270950B1 (en) 2021-04-21
WO2016150926A1 (en) 2016-09-29
JP2018512844A (ja) 2018-05-24
DK3270950T3 (da) 2021-06-07
CN107636011A (zh) 2018-01-26
AU2016236297B2 (en) 2020-07-23
BR112017020008A2 (pt) 2018-06-19
BR112017020008A8 (pt) 2023-05-02
US20180105574A1 (en) 2018-04-19
CN107636011B (zh) 2021-07-02
CA2979812C (en) 2023-08-29
EP3270950A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
Li et al. OM‐LV20, a novel peptide from odorous frog skin, accelerates wound healing in vitro and in vivo
Saïd-Sadier et al. Alarmins, inflammasomes and immunity
Zhu Gap junction-dependent and-independent functions of Connexin43 in biology
Zhang et al. Cathelicidin-BF, a novel antimicrobial peptide from Bungarus fasciatus, attenuates disease in a dextran sulfate sodium model of colitis
Lebeer et al. The major secreted protein Msp1/p75 is O-glycosylated in Lactobacillus rhamnosus GG
US20250129133A1 (en) Fusion protein, and preparation method therefor and use thereof
Chen et al. Gasdermin D drives the nonexosomal secretion of galectin-3, an insulin signal antagonist
Santos et al. Strategies to obtain lectins from distinct sources
Ueda et al. Prothymosin α plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms
Wong et al. The therapeutic anticancer potential of marine-derived bioactive peptides: a highlight on pardaxin
Fiorini et al. Bovine seminal ribonuclease triggers Beclin1-mediated autophagic cell death in pancreatic cancer cells
Ramírez-Carreto et al. Identification of a pore-forming protein from sea anemone Anthopleura dowii Verrill (1869) venom by mass spectrometry
Chavez et al. Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
US10323078B2 (en) Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases
Fu et al. The anti-myotoxic effects and mechanisms of Sinonatrix annularis serum and a novel plasma metalloproteinase inhibitor towards Deinagkistrodon acutus envenomation
Pires et al. Sulfated polysaccharide extracted of the green algae Caulerpa racemosa increase the enzymatic activity and paw edema induced by sPLA2 from Crotalus durissus terrificus venom
CN101607992A (zh) 奶牛血液中分离出的抗菌肽及其编码序列和用途
CN106674329A (zh) 具备抗微生物、抗癌/促进伤口愈合活性的肽及其用途
Rawson Antimicrobial Peptides from Venom: Structure, Function and Toxicity
Yan et al. The toxicity study on marine low-temperature lysozyme
RS52448B (sr) Antitumorska farmaceutska kompozicija koja sadrži polipeptidne fragmente seralizina
Zhang et al. Vam6 upregulated by lactic acid inhibits anti-tumor effects of intratumoral iNKT cells via modulating AMPK/mTOR pathways
Jalaei et al. In vitro antihistamine-releasing activity of a peptide derived from wasp venom of Vespa orientalis
Xiong et al. Mast cell extracellular granules are bioactive condensates driven by heparin and polyamine
US20240382535A1 (en) Use of Sustainable, Modified and Enhanced Aquaculture Limulus Amebocyte Lysate Protein and Hemolymph Compounds as a Biologic Broad Spectrum Antimicrobial Therapy.